Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma

• Main Authors: Sharon Del Vecchio, Robert J Ellis
• Format: Article
• Language: English
• Published: Codon Publications 2018-10-01
• Series: Journal of Kidney Cancer and VHL
• Subjects: cabozantinib; first-line therapy; metastatic renal cell carcinoma; second-line therapy
• Online Access: https://jkcvhl.com/index.php/jkcvhl/article/view/109

Cabozantinib is a multi-tyrosine kinase inhibitor used for the treatment of various solid-organ tumours. It was recently approved as a first- and second-line therapeutic for the management of advanced/metastatic renal cell carcinoma based on the results of two randomised controlled trials. The phase III METEOR trial compared cabozantinib against everolimus as a second- or greater line therapy and found benefits in progression-free and overall survival, and the phase II CABOSUN trial compared cabozantinib against sunitinib as a first-line therapeutic and found benefits in terms of progression-free survival. This review briefly summarises how cabozantinib fits into current treatment paradigms for the management of advanced renal cell carcinoma.